<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03885154</url>
  </required_header>
  <id_info>
    <org_study_id>44243</org_study_id>
    <nct_id>NCT03885154</nct_id>
  </id_info>
  <brief_title>Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine</brief_title>
  <official_title>Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine: An Open-Label Randomized Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kimberly S Jones</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare clinical efficacy and tolerability of valproic acid&#xD;
      (VPA) therapy versus dihydroergotamine (DHE) as abortive therapy in pediatric migraine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare valproic acid (VPA) and dihydroergotamine (DHE) alone&#xD;
      and sequentially in the treatment of pediatric migraines.&#xD;
&#xD;
      Inpatient pediatric migraine patients (based on International Classification of Headache&#xD;
      Disorders, ICHD-II criteria) or those admitted to the University of Kentucky emergency&#xD;
      department will receive standard of care acute headache management as per AAP/AAN guidelines.&#xD;
      Those who fail to respond will be considered for further eligibility. Informed consent/assent&#xD;
      will be obtained from the patients, parents or legal guardian.&#xD;
&#xD;
      Baseline labs will be collected prior to the start of the study.&#xD;
&#xD;
        1. Complete Blood Count (CBC)&#xD;
&#xD;
        2. Comprehensive Metabolic Panel (CMP)&#xD;
&#xD;
        3. Prothrombin Time/Activated Partial Thromboplastin Time/International Normalized Ratio&#xD;
           (PT/APTT/INR)&#xD;
&#xD;
        4. Magnesium and phosphorous&#xD;
&#xD;
      Patients will initially be randomized into two groups (VPA or DHE) and treated for 24 hours.&#xD;
      Those patients whose migraines resolve will end the study at 24 hours. Patients who are&#xD;
      refractory to treatment will switch interventions and continue treatment for an additional 24&#xD;
      hours.&#xD;
&#xD;
      Intervention 1: VPA Intervention 2: DHE&#xD;
&#xD;
      Patients in Group 1 will be treated with VPA for 24 hours. They will be given an initial dose&#xD;
      of IV VPA at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum&#xD;
      levels of VPA will be checked at 4 and 24 hours; depending on drug levels they may also be&#xD;
      checked at 8 and 12 hours. The target serum concentration is 100 (+/-10) ug/mL.&#xD;
&#xD;
      Patients in Group 2 will be treated with DHE for 24 hours. Dosing will be weight-based with&#xD;
      no single dose &gt;1mg and total 24 hour dose &lt;3mg.&#xD;
&#xD;
      0 hour: 0.5 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.0&#xD;
      x (wt in kg) x (0.014) =Xmg&#xD;
&#xD;
      Patients will be assessed for migraine severity at baseline, 4, 8, 12, and 24 hours.&#xD;
&#xD;
        1. pain (using the standard 0-10 point VAS pain scale)&#xD;
&#xD;
        2. presence or absence of photophobia&#xD;
&#xD;
        3. presence or absence of phonophobia&#xD;
&#xD;
        4. presence or absence of nausea&#xD;
&#xD;
      The endpoint criterion is successful migraine resolution (improvement in VAS and resolution&#xD;
      of photophobia, phonophobia, and nausea). Patients meeting this criterion will not continue&#xD;
      forward in the study.&#xD;
&#xD;
      At 24 hours, those patients that are refractory to treatment will cross over to the alternate&#xD;
      intervention, i.e. patients receiving VPA first will then get DHE, and patients receiving DHE&#xD;
      first will then get VPA. Outcomes will be measured for the next 24 hour period as described&#xD;
      above.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty recruiting participants&#xD;
  </why_stopped>
  <start_date type="Actual">October 3, 2017</start_date>
  <completion_date type="Actual">March 19, 2019</completion_date>
  <primary_completion_date type="Actual">March 19, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Perception</measure>
    <time_frame>Baseline to 24 hours</time_frame>
    <description>Change in pain perception measured by the 10-point visual analogue scale (VAS), where 0 is &quot;no pain&quot; and 10 is &quot;pain as bad as it could be.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Presence of Photophobia</measure>
    <time_frame>Baseline, 4, 8, 12 and 24 hours</time_frame>
    <description>Presence of absence of photophobia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Presence of Phonophobia</measure>
    <time_frame>Baseline, 4, 8, 12 and 24 hours</time_frame>
    <description>Presence of absence of phonophobia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Presence of Nausea</measure>
    <time_frame>Baseline, 4, 8, 12 and 24 hours</time_frame>
    <description>Presence or absence of nausea</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Migraine in Children</condition>
  <arm_group>
    <arm_group_label>Valproic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dihydroergotamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cross-Over to Dihydroergotamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cross-Over to Valproic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid (VPA)</intervention_name>
    <description>IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours</description>
    <arm_group_label>Cross-Over to Dihydroergotamine</arm_group_label>
    <arm_group_label>Cross-Over to Valproic Acid</arm_group_label>
    <arm_group_label>Valproic Acid</arm_group_label>
    <other_name>Depakene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroergotamine (DHE)</intervention_name>
    <description>0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
    <arm_group_label>Cross-Over to Dihydroergotamine</arm_group_label>
    <arm_group_label>Cross-Over to Valproic Acid</arm_group_label>
    <arm_group_label>Dihydroergotamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acute migraine as per ICHD-II criteria&#xD;
&#xD;
          -  pediatric (age 10-18)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For Valproic Acid (VPA)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Liver disease (Acute or Chronic)&#xD;
&#xD;
          -  Urea Cycle Disorder&#xD;
&#xD;
          -  Mitochondrial Disease&#xD;
&#xD;
        For Dihydroergotamine (DHE)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Peripheral vascular disease, coronary heart disease&#xD;
&#xD;
          -  History of cerebrovascular event&#xD;
&#xD;
          -  Severe or poorly controlled hypertension&#xD;
&#xD;
          -  Impaired liver or renal function&#xD;
&#xD;
          -  Triptan given in last 24 hours&#xD;
&#xD;
          -  Hemiplegic migraine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <results_first_submitted>July 23, 2021</results_first_submitted>
  <results_first_submitted_qc>September 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 7, 2021</results_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Kimberly S Jones</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Headache</keyword>
  <keyword>Valproic acid</keyword>
  <keyword>Dihydroergotamine</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihydroergotamine</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03885154/Prot_SAP_ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Valproic Acid</title>
          <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours</description>
        </group>
        <group group_id="P2">
          <title>Dihydroergotamine</title>
          <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
        </group>
        <group group_id="P3">
          <title>Cross-Over to Dihydroergotamine</title>
          <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
        </group>
        <group group_id="P4">
          <title>Cross-Over to Valproic Acid</title>
          <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No participants where enrolled in the cross-over dihydroergotamine group.</population>
      <group_list>
        <group group_id="B1">
          <title>Valproic Acid</title>
          <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours</description>
        </group>
        <group group_id="B2">
          <title>Dihydroergotamine</title>
          <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
        </group>
        <group group_id="B3">
          <title>Cross-Over to Dihydroergotamine</title>
          <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
        </group>
        <group group_id="B4">
          <title>Cross-Over to Valproic Acid</title>
          <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.6" spread="1.2"/>
                    <measurement group_id="B2" value="14.1" spread="2.0"/>
                    <measurement group_id="B4" value="16.0" spread="1.4"/>
                    <measurement group_id="B5" value="15.0" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Perception</title>
        <description>Change in pain perception measured by the 10-point visual analogue scale (VAS), where 0 is &quot;no pain&quot; and 10 is &quot;pain as bad as it could be.&quot;</description>
        <time_frame>Baseline to 24 hours</time_frame>
        <population>No participants were enrolled in the cross-over to dihydroergotamine arm. Participants were analyzed on a per-arm basis. Data were not collected for DHE only for the two participants who crossed over to Valproic Acid; only the combination of treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Valproic Acid</title>
            <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Dihydroergotamine</title>
            <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
          </group>
          <group group_id="O3">
            <title>Cross-Over to Dihydroergotamine</title>
            <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
          </group>
          <group group_id="O4">
            <title>Cross-Over to Valproic Acid</title>
            <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Perception</title>
          <description>Change in pain perception measured by the 10-point visual analogue scale (VAS), where 0 is &quot;no pain&quot; and 10 is &quot;pain as bad as it could be.&quot;</description>
          <population>No participants were enrolled in the cross-over to dihydroergotamine arm. Participants were analyzed on a per-arm basis. Data were not collected for DHE only for the two participants who crossed over to Valproic Acid; only the combination of treatments.</population>
          <units>change in score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="3.6"/>
                    <measurement group_id="O2" value="-5.8" spread="2.9"/>
                    <measurement group_id="O4" value="-5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Presence of Photophobia</title>
        <description>Presence of absence of photophobia</description>
        <time_frame>Baseline, 4, 8, 12 and 24 hours</time_frame>
        <population>No participants were enrolled in the cross-over to dihydroergotamine arm. Participants were analyzed on a per-arm basis. Data were not collected for DHE only for the two participants who crossed over to Valproic Acid; only the combination of treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Valproic Acid</title>
            <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Dihydroergotamine</title>
            <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
          </group>
          <group group_id="O3">
            <title>Cross-Over to Dihydroergotamine</title>
            <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
          </group>
          <group group_id="O4">
            <title>Cross-Over to Valproic Acid</title>
            <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Presence of Photophobia</title>
          <description>Presence of absence of photophobia</description>
          <population>No participants were enrolled in the cross-over to dihydroergotamine arm. Participants were analyzed on a per-arm basis. Data were not collected for DHE only for the two participants who crossed over to Valproic Acid; only the combination of treatments.</population>
          <units>percentage of participants w/photophobia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Presence of Phonophobia</title>
        <description>Presence of absence of phonophobia</description>
        <time_frame>Baseline, 4, 8, 12 and 24 hours</time_frame>
        <population>No participants were enrolled in the cross-over to dihydroergotamine arm. Participants were analyzed on a per-arm basis. Data were not collected for DHE only for the two participants who crossed over to Valproic Acid; only the combination of treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Valproic Acid</title>
            <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Dihydroergotamine</title>
            <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
          </group>
          <group group_id="O3">
            <title>Cross-Over to Dihydroergotamine</title>
            <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
          </group>
          <group group_id="O4">
            <title>Cross-Over to Valproic Acid</title>
            <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Presence of Phonophobia</title>
          <description>Presence of absence of phonophobia</description>
          <population>No participants were enrolled in the cross-over to dihydroergotamine arm. Participants were analyzed on a per-arm basis. Data were not collected for DHE only for the two participants who crossed over to Valproic Acid; only the combination of treatments.</population>
          <units>percentage of participants w/phonophobia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Presence of Nausea</title>
        <description>Presence or absence of nausea</description>
        <time_frame>Baseline, 4, 8, 12 and 24 hours</time_frame>
        <population>No participants were enrolled in the cross-over to dihydroergotamine arm. Participants were analyzed on a per-arm basis. Data were not collected for DHE only for the two participants who crossed over to Valproic Acid; only the combination of treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Valproic Acid</title>
            <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Dihydroergotamine</title>
            <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
          </group>
          <group group_id="O3">
            <title>Cross-Over to Dihydroergotamine</title>
            <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
          </group>
          <group group_id="O4">
            <title>Cross-Over to Valproic Acid</title>
            <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Presence of Nausea</title>
          <description>Presence or absence of nausea</description>
          <population>No participants were enrolled in the cross-over to dihydroergotamine arm. Participants were analyzed on a per-arm basis. Data were not collected for DHE only for the two participants who crossed over to Valproic Acid; only the combination of treatments.</population>
          <units>percentage of participants w/nausea</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were assessed at baseline, 4 hour, 8 hour, 12, 24 hours per intervention.</time_frame>
      <desc>No participants were enrolled in the cross-over to dihydroergotamine arm so there was no risk for all-cause mortality.</desc>
      <group_list>
        <group group_id="E1">
          <title>Valproic Acid</title>
          <description>An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.&#xD;
Valproic Acid (VPA): IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours</description>
        </group>
        <group group_id="E2">
          <title>Dihydroergotamine</title>
          <description>Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose &gt;1mg and not exceeding 3mg over 24 hours.&#xD;
Dihydroergotamine (DHE): 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tightness in chest</sub_title>
                <description>Participant experienced chest tightness that resolved in 15 to 20 minutes</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Participant experienced dyspnea and anxiety</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimberly Jones, MD</name_or_title>
      <organization>University of Kentucky</organization>
      <phone>859-218-5011</phone>
      <email>kimberly.jones@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

